HRP20160183T1 - Arilamidi bifenil-4-il-sulfonske kiseline i njihova uporaba kao terapeutskih sredstava - Google Patents

Arilamidi bifenil-4-il-sulfonske kiseline i njihova uporaba kao terapeutskih sredstava Download PDF

Info

Publication number
HRP20160183T1
HRP20160183T1 HRP20160183T HRP20160183T HRP20160183T1 HR P20160183 T1 HRP20160183 T1 HR P20160183T1 HR P20160183 T HRP20160183 T HR P20160183T HR P20160183 T HRP20160183 T HR P20160183T HR P20160183 T1 HRP20160183 T1 HR P20160183T1
Authority
HR
Croatia
Prior art keywords
independently
ring
bone
compound according
image
Prior art date
Application number
HRP20160183T
Other languages
English (en)
Croatian (hr)
Inventor
Iain Robert Greig
't Hof Robert Jurgen Van
Stuart Hamilton Ralston
Original Assignee
The Univ Court Of The Univ Of Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Univ Court Of The Univ Of Aberdeen filed Critical The Univ Court Of The Univ Of Aberdeen
Publication of HRP20160183T1 publication Critical patent/HRP20160183T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HRP20160183T 2007-03-21 2008-03-20 Arilamidi bifenil-4-il-sulfonske kiseline i njihova uporaba kao terapeutskih sredstava HRP20160183T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0705400.0A GB0705400D0 (en) 2007-03-21 2007-03-21 Therapeutic compounds andm their use
PCT/GB2008/000989 WO2008114022A1 (en) 2007-03-21 2008-03-20 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents
EP08718826.4A EP2137141B1 (en) 2007-03-21 2008-03-20 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents

Publications (1)

Publication Number Publication Date
HRP20160183T1 true HRP20160183T1 (hr) 2016-03-25

Family

ID=38024559

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160183T HRP20160183T1 (hr) 2007-03-21 2008-03-20 Arilamidi bifenil-4-il-sulfonske kiseline i njihova uporaba kao terapeutskih sredstava

Country Status (11)

Country Link
US (1) US8524778B2 (enExample)
EP (1) EP2137141B1 (enExample)
JP (1) JP5450105B2 (enExample)
CA (1) CA2681320C (enExample)
DK (1) DK2137141T3 (enExample)
ES (1) ES2561163T3 (enExample)
GB (1) GB0705400D0 (enExample)
HR (1) HRP20160183T1 (enExample)
HU (1) HUE028656T2 (enExample)
SI (1) SI2137141T1 (enExample)
WO (1) WO2008114022A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
GB0817208D0 (en) * 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
WO2012035171A2 (en) * 2010-09-17 2012-03-22 Kancera Ab New compounds
US9422224B2 (en) 2011-06-13 2016-08-23 Ergon Pharmaceuticals Llc Methods of treatment using a BCAT1 inhibitor
US10941109B2 (en) 2011-06-13 2021-03-09 Ergon Pharmaceuticals Llc Compositions and methods of treatment using a BCAT1 inhibitor
US9708276B2 (en) 2011-10-12 2017-07-18 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer
ES2649116T3 (es) * 2011-12-22 2018-01-10 Kancera Ab Bisarilsulfonamidas útiles en el tratamiento de inflamación y cáncer
BR112015007862A2 (pt) * 2012-12-10 2017-07-04 Hoffmann La Roche derivados benzil sulfonamida como moduladores rorc
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
CA2924527C (en) 2013-09-20 2022-07-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compounds for treating prostate cancer
US20160257657A1 (en) 2013-09-20 2016-09-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
HUE057569T2 (hu) 2014-12-17 2022-05-28 Pimco 2664 Ltd N-(4-hidroxi-4-metil-ciklohexil)-4-fenil-benzolszulfonamid és N-(4-hidroxi-4-metil-ciklohexil)-4-(2-piridil)-benzolszulfonamid vegyületek és terápiás alkalmazásuk
US10980806B2 (en) 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
EP3580571B1 (en) 2017-02-07 2023-06-07 Lyfstone B.V. Biomarkers for diagnosing implant related risk of implant revision due to aseptic loosening
WO2020097408A1 (en) * 2018-11-09 2020-05-14 Nimbus Artemis, Inc. Acly inhibitors and uses thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB597810A (en) 1943-04-12 1948-02-04 Gen Printing Ink Corp Improvements in or relating to derivatives of diphenyl
DE1046220B (de) 1956-04-21 1958-12-11 Bayer Ag Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen
US4119784A (en) * 1977-07-01 1978-10-10 American Cyanamid Company Anionic substituted sulfonamido biphenyls
GB2001307A (en) * 1977-07-01 1979-01-31 American Cyanamid Co Sulphonamide blood complement inhibitors
DE3000519A1 (de) 1979-02-01 1980-08-14 Byk Gulden Lomberg Chem Fab Sulfonamido-alkansaeuren, ihre verwendung und herstellung sowie sie enthaltende arzneimittel
DE3535167A1 (de) * 1985-10-02 1987-04-09 Boehringer Mannheim Gmbh Neue sulfonyl-phenyl(alkyl)amine, verfahren zu ihrer herstellung sowie arzneimittel
IL118325A0 (en) 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
SK56798A3 (en) 1995-10-30 1998-12-02 Smithkline Beecham Corp Protease inhibitors, pharmaceutical composition containing them and their use
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
AU2421797A (en) 1996-03-15 1997-10-01 Du Pont Pharmaceuticals Company Spirocycle integrin inhibitors
BR9710752A (pt) 1996-07-22 1999-08-17 Monsanto Co Inbidores de metaloprotease de sulfonamida de tiol
DE69709160T2 (de) 1996-10-16 2002-08-14 American Cyanamid Co., Madison Herstellung und anwendung von ortho-sulfonamido-aryl-hydroxamsäuren als matrix-metalloproteinase- und tace-inhibitoren
PT944619E (pt) 1996-11-27 2007-01-31 Bristol Myers Squibb Pharma Co Novos antagonistas dos receptores da integrina
WO1998043962A1 (en) 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
EP0983228A4 (en) 1997-05-08 2002-08-07 Smithkline Beecham Corp PROTEASE INHIBITORS
DE19719621A1 (de) 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
ATE210639T1 (de) 1997-05-09 2001-12-15 Hoechst Ag Substituierte diaminocarbonsäuren
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
BR9907735A (pt) 1998-01-23 2000-10-17 Aventis Pharma Gmbh Derivados de sulfonamida como inibidores da reabsorção óssea e como inibidores da aderência celular
PL342009A1 (en) 1998-02-04 2001-05-07 Novartis Ag Sulphonylamine derivatives capable to inhibit extracellular substance degrading metaloproteinases
JPH11246527A (ja) 1998-03-02 1999-09-14 Shionogi & Co Ltd Ｍｍｐ−８阻害剤
EP0960882A1 (en) 1998-05-19 1999-12-01 Hoechst Marion Roussel Deutschland GmbH Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
KR20030005230A (ko) * 2000-03-21 2003-01-17 더 프록터 앤드 갬블 캄파니 Ｎ-치환된 메탈로프로테아제 저해제를 함유하는 탄소환식측쇄
US6723733B2 (en) 2000-05-19 2004-04-20 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses
AU2002228316A1 (en) 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
WO2002074298A1 (en) 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Il-6 production inhibitors
US6849635B2 (en) * 2001-05-07 2005-02-01 Smithkline Beecham Corporation Sulfonamides
MXPA04001253A (es) 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
GB0126157D0 (en) * 2001-10-31 2002-01-02 Univ Aberdeen Therapeutic compounds
TW200305396A (en) 2002-03-27 2003-11-01 Shionogi & Co Cartilage extracellular matrix degradation
JP4881558B2 (ja) 2002-09-04 2012-02-22 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
DE10251170A1 (de) * 2002-10-31 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2004073619A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
US7572825B2 (en) * 2003-05-07 2009-08-11 The University Court Of The University Of Aberdeen Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions
WO2004106290A1 (ja) 2003-05-14 2004-12-09 Kissei Pharmaceutical Co., Ltd. アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途
GB0324792D0 (en) * 2003-10-23 2003-11-26 Sterix Ltd Compound
BRPI0417687A (pt) 2003-12-19 2007-04-03 Pfizer derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade
US7326732B2 (en) * 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
GB0405193D0 (en) * 2004-03-08 2004-04-21 Medical Res Council Compounds
JP2007536348A (ja) 2004-05-05 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ スルホンアミド誘導体
GB0412553D0 (en) 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
US7470722B2 (en) * 2004-06-10 2008-12-30 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
EP1659113A1 (en) 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
KR20080016649A (ko) 2005-06-16 2008-02-21 화이자 인코포레이티드 Ｎ-(피리딘-2-일)-술폰아미드 유도체
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
TW200720261A (en) * 2005-08-31 2007-06-01 Sankyo Co Phenylene derivatives
WO2007089335A2 (en) * 2005-12-29 2007-08-09 Lexicon Pharmaceutical Inc. Multicyclic amino acid derivatives and methods of their use
US7560597B2 (en) * 2007-03-08 2009-07-14 The University Court Of The University Of Aberdeen 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
GB0817207D0 (en) * 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use

Also Published As

Publication number Publication date
EP2137141A1 (en) 2009-12-30
US20100286266A1 (en) 2010-11-11
ES2561163T3 (es) 2016-02-24
DK2137141T3 (en) 2016-02-29
EP2137141B1 (en) 2015-12-02
WO2008114022A1 (en) 2008-09-25
CA2681320A1 (en) 2008-09-25
CA2681320C (en) 2015-05-19
US8524778B2 (en) 2013-09-03
GB0705400D0 (en) 2007-05-02
HUE028656T2 (en) 2016-12-28
JP5450105B2 (ja) 2014-03-26
SI2137141T1 (sl) 2016-03-31
JP2010522152A (ja) 2010-07-01

Similar Documents

Publication Publication Date Title
AU2019321434B2 (en) Pyrrolo - dipyridine compounds
JP7380507B2 (ja) Ｓｔｉｎｇ作動化合物
JP6721499B2 (ja) 骨の成長を促進するためのアルキルアミンハルミン誘導体
JP2010522152A5 (enExample)
SI2459176T1 (en) Crystallization process and bioavailability
JP2007501281A5 (enExample)
JP4582456B2 (ja) ８−アザプロスタグランジン誘導体およびその医薬用途
RU2005122901A (ru) Производные пиридино [2,3-] пиримидина в качестве селективных ингибиторов kdr и fgfr
CN101941990A (zh) 哌嗪和取代的哌啶抗病毒药物的前药
EA002822B1 (ru) Антагонисты рецептора интегрина
JP2025090543A (ja) フルオロβ－カルボリン化合物
WO2018202039A1 (zh) 杂环化合物及其制备方法
RU2002102495A (ru) Новые производные ксантона, их получение и применение в качестве лекарственного средства
ES2263033T3 (es) Derivados de pirodoindolona sustituidos en posicion 3 con un grupo heterociclico, su preparacion y su aplicacion en terapeutica.
AU2019362658B2 (en) Conjugates of hyaluronic acid and aminobisphosphonates and the therapeutic use thereof
ITMI970730A1 (it) Coniugati di bis-fosfanati con funzionalita' alchilanti aventi attivita' antitumorale
TWI492920B (zh) 水楊酸苯胺衍生小分子之醫藥組合物及其製備與醫藥用途
RU2019111768A (ru) Противораковые агенты и их получение
AU759249B2 (en) Barbituric acid derivative and preventive and therapeutic agent for bone and cartilage containing the same
CN1953985B (zh) 哌嗪和取代的哌啶抗病毒药物的前药
RU2024116795A (ru) Конъюгат антитела к trop2 человека с камптотециновым лекарственным средством и его медицинское применение
KR20170091610A (ko) 신규 peg 유도체
CN122029214A (zh) 一种磷脂药物偶联物及其制备方法和用途
JP2013541515A (ja) 表面機能化のためのアダマンチル基本構造を有する三脚型ビスホスホネート誘導体の合成
RU2006126061A (ru) Производные 2-(гетеро)арил-замещенных тетрагидрохинолинов